PharmaCyte closer to submitting IND with successful completion of clinical trial product
PharmaCyte has now moved one step closer to submitting an IND to the FDA to request a clinical trial in locally advanced, inoperable pancreatic cancer in the U.S. The company has successfully completed the first of two manufacturing runs to produce the clinical trial product. October 16, 2019